CRISPR Therapeutics Future Growth
Future criteria checks 2/6
CRISPR Therapeutics is forecast to grow earnings and revenue by 34.5% and 54.6% per annum respectively. EPS is expected to grow by 35.2% per annum. Return on equity is forecast to be -10.4% in 3 years.
Key information
34.5%
Earnings growth rate
35.2%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 54.6% |
| Future return on equity | -10.4% |
| Analyst coverage | Good |
| Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07
Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 534 | -262 | -294 | -269 | 16 |
| 12/31/2025 | 132 | -446 | -370 | -347 | 26 |
| 12/31/2024 | 14 | -431 | -182 | -149 | 25 |
| 9/30/2024 | 203 | -240 | -191 | -189 | N/A |
| 6/30/2024 | 202 | -266 | -129 | -122 | N/A |
| 3/31/2024 | 272 | -217 | -169 | -159 | N/A |
| 12/31/2023 | 371 | -154 | -272 | -260 | N/A |
| 9/30/2023 | 170 | -354 | -295 | -278 | N/A |
| 6/30/2023 | 170 | -416 | -362 | -343 | N/A |
| 3/31/2023 | 100 | -524 | -377 | -352 | N/A |
| 12/31/2022 | 1 | -650 | -533 | -496 | N/A |
| 9/30/2022 | 14 | -681 | -509 | -468 | N/A |
| 6/30/2022 | 15 | -633 | -516 | -445 | N/A |
| 3/31/2022 | 915 | 312 | 414 | 504 | N/A |
| 12/31/2021 | 915 | 378 | 457 | 539 | N/A |
| 9/30/2021 | 902 | 412 | 465 | 544 | N/A |
| 6/30/2021 | 902 | 447 | 502 | 549 | N/A |
| 3/31/2021 | 1 | -392 | -309 | -287 | N/A |
| 12/31/2020 | 1 | -349 | -257 | -238 | N/A |
| 9/30/2020 | 77 | -211 | -167 | -154 | N/A |
| 6/30/2020 | 289 | 20 | 45 | 55 | N/A |
| 3/31/2020 | 289 | 46 | 40 | 48 | N/A |
| 12/31/2019 | 290 | 67 | 50 | 57 | N/A |
| 9/30/2019 | 213 | -11 | 18 | 25 | N/A |
| 6/30/2019 | 1 | -200 | -133 | -128 | N/A |
| 3/31/2019 | 2 | -185 | -121 | -117 | N/A |
| 12/31/2018 | 3 | -165 | -99 | -96 | N/A |
| 9/30/2018 | 35 | -117 | -85 | -83 | N/A |
| 6/30/2018 | 37 | -91 | N/A | -79 | N/A |
| 3/31/2018 | 40 | -75 | N/A | -69 | N/A |
| 12/31/2017 | 41 | -68 | N/A | -70 | N/A |
| 9/30/2017 | 11 | -51 | N/A | -75 | N/A |
| 6/30/2017 | 10 | -41 | N/A | -71 | N/A |
| 3/31/2017 | 7 | -36 | N/A | -69 | N/A |
| 12/31/2016 | 5 | -23 | N/A | -53 | N/A |
| 9/30/2016 | 3 | -53 | N/A | 33 | N/A |
| 6/30/2016 | 2 | -44 | N/A | 40 | N/A |
| 3/31/2016 | 1 | -31 | N/A | 51 | N/A |
| 12/31/2015 | 0 | -26 | N/A | 59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRSP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRSP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRSP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRSP's revenue (54.6% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: CRSP's revenue (54.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRSP is forecast to be unprofitable in 3 years.